COMPUTEX TAIPEI 2019 Exhibitor Profiles
![](https://i1.wp.com/picante.today/wp-content/uploads/2019/05/businessWireLogo.jpg?fit=150%2C150&ssl=1)
TAIPEI–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/AIoT?src=hash” target=”_blank”gt;#AIoTlt;/agt;–COMPUTEX TAIPEI 2019 runs May 28 – June 1, 2019 at the Taipei World
Trade Center, Taipei Nangang Exhibition Center, and the Taipei
International Convention Center (TICC). Business Wire is the official
news distribution partner for COMPUTEX. Listed below are
exhibitor profiles.
Company: | Aeromax Technology Co., Ltd. |
Booth: | S1216 |
Web: | http://www.aeromax.com.tw/ |
Aeromax, founded in June 2006, aims to be a total solution provider in the Digital STB, Android TV, Audio sound card and Professional/Industrial electronics industry. |
|
Our products are designed and made in Taiwan and many OEM/ODM customers have continuously regarded Aeromax as their partner because of our dedication to creating high quality products. |
|
Recently launched: | |
AW1500_15W Walnut Casing Wireless Fast Charger. | |
It features premium brass construction and polished handmade walnut casing. |
|
With excellent quality and safety, we’re sure the AW1500 (made in Taiwan) can bring the best charging experience to our customers. |
|
Company: | ATrack Technology Inc. |
Booth: | SmarTEX – S0810a |
Ticker Symbol & Exchange: | TPEX:6465 |
Web: | www.atrack.com.tw |
ATrack (TPEX: 6465) specializes in telematics hardware designing and manufacturing. |
|
Our core R&D team has over 15 years of industry experience, and our products have been deployed in various operating environments worldwide. |
|
ATrack has also been particularly successful at performing user-specific firmware and hardware customizations to help our clients win projects in this dynamic market. Through our continuous commitment to the industry and providing unmatched level of responsiveness, we have been recognized as one of the most reliable hardware partners. |
|
Company: | BIN YUANN FIRSTLINE INDUSTRIAL CORP. |
Booth: | Q1334a |
Web: | www.binyuann.com |
Bin Yuann specializes in the exporting of server chassis rails and cabinets. |
|
The company was recognized by ASIG Germany for our outstanding quality and performance. |
|
Company: | CERVOZ |
Booth: | K0303a |
Web: | www.cervoz.com |
Cervoz develops, produces, and markets storage and memory products for industrial applications. |
|
Everything we do, from design, product management, and manufacturing, to quality control, sales and service is dedicated to fulfilling the special characteristics of diversified and critical industrial applications. |
|
We are able to offer our high quality embedded products with legacy and mainstream technology, long-term availability, BOM (bill of material) control, high reliability, and top compatibility. |
|
Company: | CINCOZE |
Booth: | K0208 |
Web: | www.cincoze.com |
Cincoze is a professional manufacturer of embedded computing platforms. |
|
We design, manufacture, and market rugged fanless computers, industrial panel PCs, and monitors for harsh and demanding environments. With its leading-edge products and application-driven functionalities, Cincoze enables new technologies and solutions for multiple applications, including factory automation, machine automation, machine vision, in-vehicle computing, intelligent transportation, and surveillance. |
|
Company: | Clientron Corp. |
Booth: | R0827, Nangang Hall2 |
Ticker Symbol & Exchange: | 8119 |
Web: | www.clientron.com |
Clientron was founded in 1983. The company is dedicated in providing global intelligent solutions to our clients. With design, manufacturing and service abilities, Clientron offers high-quality and high-performance computing platforms including Thin Client, POS, Automotive Electronics and Intelligent Embedded Systems. We commit to continuously provide better IoT client solutions and services for our partners and customers to build an intelligent e-World. Visit us at www.clientron.com. |
|
Company: | CyberLink |
Booth: | S0704a |
Ticker Symbol & Exchange: | TSE: 5203 |
Web: | www.cyberlink.com/faceme |
Founded in 1996, CyberLink Corp. is the world leader in multimedia software and AI facial recognition technology. CyberLink addresses the demands of consumer, commercial and education markets through a wide range of solutions, covering digital content creation, multimedia playback, video conferencing, live casting, mobile applications and AI facial recognition. |
|
With years of research in the fields of artificial intelligence and facial recognition, CyberLink developed the FaceMe® Facial Recognition Engine. Powered by deep learning algorithms, FaceMe® delivers reliable, high-precision, and real-time facial recognition that is critical to AIoT applications like smart retail, smart security, and surveillance, smart city, and smart home. |
|
Company: | Diwei Industrial Co., Ltd. |
Booth: | Nangang Hall 2, 1F Q1016 |
Web: | http://www.diwei.com |
Diwei Industrial Co., Ltd. is a leading manufacturer of LCD monitor arms and ergonomic TV wall mounting products, including computer monitor arms, healthcare arms, medical trolleys, TV wall mounts, projector mounts, TV stands, mobile TV carts, whiteboard stands, and POS mounts. |
|
ODM & OEM projects are welcome. We can offer you all kinds of ergonomic mounting products with high quality, competitive pricing and the best service. |
|
Company: | Fonebud IoT Berhad |
Booth: | A0817a |
Web: | www.fonebud.com |
Mobile Sharing Assistant (MSA) integrates blockchain technology and tourism, provides free language translation, data roaming and travel information services for tourists! |
|
We developed MSA to assist travelers with barrier-free communication and internet services through the collection of data on their travel habits. |
|
Our focus is to provide free roaming data: visitors pays deposit for the device and earn points by viewing short advertisements. Points may then be exchanged for roaming data, airline tickets, accommodation, etc. Travelers may also convert points to cash through the app. |
|
The translation engine of the MSA allows direct live translation, instant photo translation, conference translation. |
|
MSA technologies, Neural Machine Translation (NMT) and e-SIM, have both been tested and confirmed in real world situations, enabling users to have a pleasant language barrier-free journey. |
|
Company: | Ganzin Technology Inc. |
Booth: | TWTC Hall 1, A1219 |
Web: | https://ganzin.com/ |
GANZIN, an award winning Taiwan startup, stirred up the AR/VR scene with an introduction of a breakthrough eye-tracking module – Aurora – that promises to dramatically expand on how eye-tracking can play a beneficial role in our lives. |
|
Ganzin has ingeniously re-designed the necessary algorithms for a highly precise eye-tracking module, and dramatically re-architected its form factor and power requirements. |
|
Ganzin Aurora eye tracking module features seamless integration, simple mechanical design, all-day battery life, and unbound usage scenarios. GANZIN is positioning itself as a key solution provider to help customers to elevate eye tracking user experiences to the next level. |
|
Company: | Gosuncnwelink Technology Co., Ltd. |
Booth: | K1223a |
Web: | www.gosuncnwelink.com |
GosuncnWelink Technology is dedicated to the development, production and marketing of cellular M2M Modules, connected car solutions and intelligent broadband products. |
|
GosuncnWelink’s high-performance M2M modules deliver wireless connectivity with a variety of air interfaces, covered GSM/GPRS, CDMA 1X/EV-DO, WCDMA/HSPA/HSPA+, LTE TDD and LTE FDD, LTE Cat-M1/NB-IoT. |
|
By combining the abundant experience in telecommunication and automotive electronics, GosuncnWelink can provide “device solution” or “device + platform total solution” according to the situation of the customer’s platform construction in different countries. |
|
GosuncnWelink’s connected car solutions deliver reliable products and services to our partners including AT&T, T-Mobile, Telia Sonera, etc. |
|
Company: | HABOOK Information Technology Inc. |
Booth: | S0817 |
Web: | http://www.habook.com.tw/english/ |
HABOOK Group, founded in 1999, has established more than 50,000 Smarter Classrooms in over 3,000 schools around the world. |
|
Having thousands of Smarter Classrooms is only the first step as we aim to spread our successful models around the world, and help teachers, students, parents, and schools get actual benefits from the awesome experiences |
|
We have developed IoT, Big Data, and AI in education technology, and created a new ecosystem of Smarter Education. Our ultimate goal is to empower teaching and inspire learning. |
|
Company: | HKF Technology Co., Ltd. |
Booth: | TNEC 2 S0423 |
Web: | www.hkfcom.com |
HKF Technology Co., Ltd. is one of the world’s leading manufacturers and exporters of monitors since 1996. |
|
HKF develops: 7”~24” TFT-LCD computer screens; 15”~19” monitor TVs; 15”~19” CCTV monitors for the security market; 26”~52” TFT-LCD LVs; and open frame TFT-LCD modules for various applications in the banking, gaming, amusement, and advertising industries. |
|
HKF is one of the most well reputed and known brands in the world of technology. HKF is able to offer you sustainable pricing, quality, and availability. |
|
Company: | ICPDAS |
Booth: | K0316 |
Ticker Symbol & Exchange: | 3577 |
Web: | http://www.icpdas.com |
ICP DAS, established in 1993, focuses on innovation and improving industrial automation technology. ICP DAS strives to create advanced remote I/O controllers, distributed I/O modules, and I/O data acquisition boards. |
|
To provide a total industrial automation solution, ICP DAS developed a series of programmable automation controller, motion-control systems and web-related products. |
|
Company: | JAFCO Taiwan Capital |
Booth: | A0917a |
Web: | http://www.jafcoasia.com/ |
JAFCO Taiwan Capital was established in Taiwan by JAFCO Asia, which is the subsidiary of JAFCO Co., Ltd., Japan’s largest venture capital Group (TYO: 8595). |
|
In the past 18 years, JAFCO Taiwan’s operation has invested over 70 companies with 25 successful exits, out of which 20 were successfully listed. |
|
This is the first time JAFCO Taiwan Capital leads 5 of our portfolios – Deluxe Technology, Aeolus Robotics, Artilux Inc., ACT Genomics and Taiwan Advanced Nanotech – to join InnoVEX. |
|
Through the event, we hope to connect with potential buyers and investors. We look forward to building great business with you! |
|
Company: | LAN Accessories Co., Ltd. |
Booth: | Q1217 |
Web: | www.lanacc.com.tw |
LAN Accessories Co., Ltd, established in 2001, specializes in USB extenders, USB repeaters & USB extenders via Cat5/5e/6 and a wide range of computer cable assemblies. |
|
Our products are fully compliant with RoHS, CE and FCC regulations which can help extend business opportunities into USA, Europe, Asia and other countries throughout the world. |
|
Excellent quality, stylish design, on time delivery, competitive pricing and value-added services are the main factors for our success in the worldwide market. |
|
As a major supplier in the computer peripherals and cable industry since 2001, LAN Accessories has earned a fine reputation for its quality and reliability. We always honor our commitments and take due responsibility for our products. |
|
Company: | Leadtek Research Inc. |
Booth: | S0813 |
Ticker Symbol & Exchange: | TSE:2465 |
Web: | http://www.leadtek.com |
Established since 1986, Leadtek Research Inc. provides customers with the best quality services. |
|
Leadtek has developed into a multifaceted solution provider with main product ranges covering the zero client and thin client for desktop virtualization, graphic cards for both computer games and workstations, AI solutions, GPS, cloud computing workstations, and others, aiming to serve the global market with innovative technologies and excellent products. |
|
Company: | Maxpac Electronics Co., Limited |
Booth: | N0530 |
Web: | www.maxpac.com.cn |
Maxpac is a professional manufacturer of LCD/LED Monitors, AIO and PIO, SKD/CKD parts, and open frames. It is a high-tech private enterprise with its own research, production and marketing services. |
|
In 2009, we began research and production in Dongguan City at Jinxiongda Technology Park, which covers an area of more than 8,000 square meters. We have three production lines of PCB boards, one automatic production line of ABU LCD monitors, and full sets of testing and lab machines for quality control. The yearly production capacity is 300K units. |
|
Based on our research ability, full technical support, high-efficiency management system, and ISO certified production management system, our quality is recognized by clients the world over. |
|
Maxpac is our legal registered trademark. We welcome all OEM and ODM orders. |
|
Company: | Prosperity Creativity Inc. |
Booth: | L0018 |
Web: | http://pci.pii.tw/ |
Prosperity Creativity Inc., established in 2011 with capital of NTD 10,000,000 and located in the World Trade Center of Taiwan, is a company that professionally integrates a virtual studio with an automatic tracking lecture recording system and holographic light board to supplement the teaching experience. |
|
We enable such smart campus features as MOOCs (Massive Open Online Courses), remote learning, classroom lecture recording, and multimedia immersion classrooms with environmental controls built in. |
|
Our products include 3D 4K virtual studio work stations, portable green/blue chroma key boards, LED lights, large holographic light boards, multi-point TV screens, on-air broadcast systems, encoder/decoders, media storage systems, and customized video website platform design. |
|
Company: | SECO |
Booth: | Hall 1 – K1015a |
Web: | www.seco.com |
SECO Group excels in the electronic embedded field, offering cutting-edge solutions for a variety of applications, through standard modules (Qseven®, COM ExpressTM, SMARC, ETX®), SBCs systems and full-custom solutions. |
|
With 40+ years of experience and more than 300 employees, SECO is constantly growing and operates globally with offices in Italy, Germany, USA, India and Taiwan. SECO manages the entire production cycle in-house, from the development and design stage to manufacturing and mass distribution. |
|
Creativity, innovation and collaborations with the most important technological partners are the foundation of SECO’s ability to meet the ever-changing challenges of the embedded market. |
|
Company: | Silicon Line GmbH |
Booth: | Hall 1 L0901a |
Web: | www.silicon-line.com |
Silicon Line GmbH (www.silicon-line.com), headquartered in Munich, the global leader in developing and providing innovative optical link technology, will be showcasing and demonstrating (in Hall 1 #L0901a) its newest technology supporting HDMI, DisplayPort, USB and VirtualLink standards at Computex. |
|
It will feature the first demonstration in Asia of active optical cables with embedded technology supporting all features of the recently released HDMI 2.1 specification. |
|
Company: | Smith |
Booth: | J0403a |
Web: | www.smithweb.com |
Founded in 1984, Smith sources, manages, and distributes the electronic components that go into everything from mobile phones and computers to appliances and directional drilling systems. |
|
Smith is always moving: helping manufacturers navigate market shifts; customizing supply chain solutions; testing components using cutting-edge technology. |
|
Offering unrivaled customer support, Smith is the leading independent distributor of electronic components and ranks 9th among all global distributors. |
|
Company: | Supermicro |
Booth: | Hall 1 N0206 |
Ticker Symbol & Exchange: | SMCI (OTC) |
Web: | https://www.supermicro.com |
Supermicro is the leading innovator in high-performance, high-efficiency server technology. |
|
We are a premier provider of advanced Server Building Block |
|
Supermicro is committed to protecting the environment through our “We Keep IT Green®” initiative. Our Resource-Saving Architecture reduces TCO and environmental impact through design innovation and efficiency to provide customers with the most energy-efficient, earth-friendly solutions available on the market. |
|
Company: | Synergies Intelligent Systems, Inc. |
Booth: | S0734 |
Web: | http://synergies.ai/ |
Founded in 2016 in Boston, Synergies Intelligent Systems, Inc. devotes to developing an AI-powered augmented decision-making system. |
|
Through data insight, behavior forecasting, and process automation, Synergies assists enterprises to accelerate business decision-making process 10 times faster. |
|
Currently, Synergies’ services have been wildly recognized and adopted, and Synergies has achieved strategic cooperation with many leading enterprises, including Foxconn Industrial Internet, SF Express, and Stark Technology, Inc. Synergies has been delivering excellent performances in different fields such as manufacturing, finance, and retail. |
|
Company: | TASHI Smartech Co., Ltd. |
Booth: | S1220 |
Web: | http://www.tashi.ute.com/ |
TASHI spirit is serving Home, Medical Institutes, School, and Office with intelligent smart solutions including Access Control, Elderly Care, Nursing Care, Home Automation, Intercom and Security. The goal of TASHI not only provides all customers considerate applications and management platforms, but also provides the integrated service of state-of-the-art technology through innovative design building with advanced AI as well as Cloud solutions. |
|
Company: | TVO PTE. LTD. (Tecware) |
Booth: | L0802 |
Web: | www.tecware.co |
For the first time, Tecware, a PC Case and Peripheral brand, will be exhibiting at COMPUTEX 2019. |
|
Visit their booth and get a hands-on experience as they introduce the brand and its latest products to the public. |
|
Tecware sets itself apart with a commitment to high quality standards and meaningful designs while balancing the price-performance ratio of its products, so consumers understand what they’re paying for and the value they are getting. |
|
Where: Taipei Nangang Exhibition Center, Hall 1, 4F, Booth No. L0802 | |
When: May 28 – June 1, 2019 | |
Company: | Unitek International Group Ltd |
Booth: | Q0104 |
Web: | www.unitek-products.com |
UNITEK is a professional computer and mobile accessories brand established in Hong Kong since 2006. |
|
Being one of the top consumer electronic and accessories brands in Asia, UNITEK is expanding globally and has established sales channels in more than 30 countries around the world. UNITEK aims to build new tech products to cover the many dimensions of human experience, and strives to make the world more friendly each day. |
|
Company: | Wentai Technology Corporation |
Booth: | I1307 |
Web: | http://www.wentailighting.com/ |
As one of the leading manufacturers of power supplies and LED lighting, Wentai Technology will debut the Aidan series Titanium PC Power at 2019 Computex, and announce its entry into the gaming and cryptocurrency mining markets. |
|
Wentai has developed cutting-edge patented technology, using MCU microcontrollers as the Aidan series of titanium power adjustment and control platform, implementing true AI digital power control to achieve the highest power efficiency among all 80 PLUS Titanium certified products. |
|
Wentai is committed to providing products and services that are energy efficient, highly reliable and customized, and looks forward to working together with more brand manufacturers. |
|
Company: | WiBASE Industrial Solutions |
Booth: | Nang Gang Hall1 K1116 |
Web: | www.wibase.com |
WiBASE is a piloting solution provider in AIoT applications headquartered in Taiwan. |
|
As a pioneering startup in AIoT, we’ve delivered many successful projects to major IIoT adopters of competitive and demanding industries such as retail, law enforcement, utilities and logistics. |
|
WiBASE is a strategic subsidiary of Wistron, a TSP (Technical Service Provider) ranked within the Fortune 500. WiBASE enjoys the advantages of manufacturing support from Wistron while playing the role of developing IIoT business for the Wistron group. |
|
Qualified members of the press please note the following important
information.
Exhibitor News:
http://www.tradeshownews.com/events/computex-taipei-2019/
Press Information:
https://www.computex-press.com.tw/
About Business Wire:
Business Wire, a Berkshire
Hathaway company, is the global leader in press
release distribution and regulatory
disclosure. Investor relations, public relations, public policy and
marketing professionals rely on Business Wire to accurately distribute
market-moving news and multimedia, host online
newsrooms and IR
websites, build content
marketing platforms, generate social engagements and provide
audience analysis that improves interaction with specified target
markets. Founded in 1961, Business Wire is a trusted source for news
organizations, journalists, investment professionals and regulatory
authorities, delivering news directly into editorial systems and leading
online news sources via its multi-patented NX Network. Business Wire has
29 offices worldwide to securely meet the varying needs of
communications professionals and news consumers.
Learn more at services.BusinessWire.com
and Tempo,
the Business Wire resource for industry trends; follow updates on
Twitter: @businesswire
or on Facebook.
Click
here to subscribe to Mobile Alerts for Business Wire.
Contacts
Jim Liebenau
+1.310.820.9473
Twitter: @tradeshownews
![](https://grassnews.net/wp-content/uploads/2019/03/Grassnews-600px.png)
Indivior
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
- Primary and Secondary End Points of the Study were Not Met
- Indivior Does Not Currently Expect to Exercise AEF0117 Option
SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ — Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma’s announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. In this phase 2B study, patients were treatment-seeking participants, 84% of whom had severe CUD.
The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD.
This clinical Phase 2B study is part of the strategic collaboration between Aelis Farma and Indivior, which includes an exclusive option for Indivior to license the global rights to AEF0117. Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favorable clinical data, Indivior does not currently expect to exercise its option.
Important Cautionary Note Regarding Forward-Looking Statements
This news release contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding whether: we will be able to ultimately demonstrate the safety and efficacy of AEF0117, which is a prerequisite to filing any New Drug Application; we might ever exercise our option for AEF0117 and, if so, when; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” “guidance,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Actual results may differ materially from those because they relate to future events. Various factors may cause differences between Indivior’s expectations and actual results, including, among others, the risks described in our most recent annual report on Form 20-F beginning on page 9 as filed with the U.S. SEC and in subsequent releases; legal and market restrictions that may limit how quickly we can repurchaser our shares; the substantial litigation and ongoing investigations to which we are or may become a party; our reliance on third parties to manufacture commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in our pipeline; our ability to comply with legal and regulatory settlements, healthcare laws and regulations, requirements imposed by regulatory agencies and payment and reporting obligations under government pricing programs; risks related to the manufacture and distribution of our products, most of which contain controlled substances; market acceptance of our products as well as our ability to commercialize our products and compete with other market participants; competition; the uncertainties related to the development of new products, including through acquisitions, and the related regulatory approval process; our dependence on third-party payors for the reimbursement of our products and the increasing focus on pricing and competition in our industry; unintended side effects caused by the clinical study or commercial use of our products; our ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions; our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings related to intellectual property rights; the risks related to product liability claims or product recalls; the significant amount of laws and regulations that we are subject to, including due to the international nature of our business; macroeconomic trends and other global developments such as armed conflicts and pandemics; the terms of our debt instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they come due; changes in applicable tax rate or tax rules, regulations or interpretations and our ability to realize our deferred tax assets; and volatility in our share price due to factors unrelated to our operating performance or that may result from the potential move of our primary listing to the U.S.
Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.
This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
References:
- National Library of Medicine (U.S.) (2022, April). Effect of AEF0117 on treatment-seeking patients with cannabis use disorder (CUD) (SICA2). Identifier
NCT05322941 https://www.clinicaltrials.gov/study/NCT05322941
Logo – https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/indivior-provides-update-on-aelis-farmas-clinical-phase-2b-study-results-with-aef0117-in-participants-with-cannabis-use-disorder-302237355.html
Innocan
Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options
![innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options](https://grassnews.net/wp-content/uploads/2024/08/61828-innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options.jpg)
HERZLIYA, Israel and CALGARY, Alberta, Aug. 29, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has completed its previously announced non-brokered private placement offering of 5,025,725 units of the Company (the “Units”) at a price of C$0.22 per Unit for gross proceeds of C$1,105,659.50 (the “Offering”).
Each Unit is comprised of: (i) one (1) common share in the capital of the Company (each a “Common Share”); and (ii) one (1) common share purchase warrant (each a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$0.32 for a period of four (4) years from the date of issuance.
Innocan intends to use the proceeds of the Offering for working capital and general corporate purposes.
The securities issued to Canadian subscribers in connection with the Offering are subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.
Iris Bincovich, Chief Executive Officer of the Company, stated “we are very pleased with our successful offering. I would like to extend my sincere gratitude to our investors for their unwavering support. We see this as a strong vote of confidence by both existing and new investors which demonstrates investor support of our vision and strategic direction. These new funds will provide us with additional working capital to enable us to capitalize on new opportunities and allow us to advance strongly on our growth plans.”
The Company is also pleased to announce that it has granted an aggregate of 300,000 stock options (each an “Option“) to certain consultants of the Company pursuant to the Company’s stock option plan (the “Plan“). Each Option may be exercised for one (1) common share in the capital of the Company (each, a “Share“) at a price of $0.25 per Share. The Options expire on August 27, 2029.
All Options granted vest in accordance with the following vesting schedule: (i) 1/3rd of the Options vested immediately at grant; (ii) 1/3rd of the Options will vest on February 28, 2025; and (iii) 1/3rd will vest on August 27, 2025; all subject to the terms and conditions of the Plan.
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Logo – https://mma.prnewswire.com/media/2046271/4883982/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options-302234455.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
![](https://grassnews.net/wp-content/uploads/2024/08/europe-medical-cannabis-market-forecast-2024-2032-tilray-aurora-cannabis-and-gw-pharmaceuticals-dominate-the-market-landscape.gif)
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
-
Cannabis2 weeks ago
Silly Nice Announces Launch of New 1G 510 Vape Cartridge and 2G All-In-One Vape in New York Dispensaries This September
-
Cannabis2 weeks ago
Cannabis Cultivation Market – Global Food Additives, Oils, Tinctures, Cannabis Indica, Cannabis Sativa Forecast 2024-2030
-
Cannabis1 week ago
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
-
Cannabis2 weeks ago
Global Hemp Based Food Market Size To Worth USD 4.87 Billion By 2033 | CAGR Of 13.12%
-
Innocan1 week ago
Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options
-
Indivior4 days ago
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder